CG
TXG icon

Cutler Group’s 10x Genomics TXG Stock Holding History

Cutler Group’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,300
Closed -$83K – 4739
2022
Q4 		$83K Buy
2,300
+120
+6% +$3.92K 0.01% 1280
2022
Q3 		$62K Buy
2,180
+1,880
+627% +$71.6K ﹤0.01% 1750
2022
Q2 		$13K Sell
300
-600
-67% -$31.1K ﹤0.01% 3026
2022
Q1 		$68K Buy
900
+50
+6% +$4.37K ﹤0.01% 1997
2021
Q4 		$126K Buy
850
+200
+31% +$30.6K 0.01% 1680
2021
Q3 		$94K Sell
650
-50
-7% -$8.58K ﹤0.01% 1966
2021
Q2 		$137K Buy
700
+500
+250% +$90.5K 0.01% 1609
2021
Q1 		$36K Sell
200
-3,420
-94% -$591K ﹤0.01% 2692
2020
Q4 		$512K Buy
+3,620
New +$525K 0.02% 617
2020
Q2 		– Sell
-600
Closed -$46.7K – 4899
2020
Q1 		$37K Buy
600
+500
+500% +$39K ﹤0.01% 1916
2019
Q4 		$7K Buy
+100
New +$6.01K ﹤0.01% 2862

Other funds holding TXG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

Cutler Group's TXG Position: Q1 2023 in Review

Cutler Group sold out of 10x Genomics (TXG) in Q1 2023, closing a stake of 2,300 shares — an estimated $83K sold.

Cutler Group first reported a position in TXG in Q4 2019 and held it in 11 quarters. The position peaked at $512K in Q4 2020. 258 funds tracked by Wall St. Rank hold TXG as of Q1 2023.

  • Cutler Group reported no remaining 10x Genomics position as of Q1 2023 after selling out during the quarter.
  • Cutler Group sold 2,300 10x Genomics shares in Q1 2023, an estimated $83K.
  • Cutler Group first reported a position in 10x Genomics in Q4 2019 and held it in 11 quarters.
  • Cutler Group's 10x Genomics position peaked at $512K in Q4 2020.
  • 258 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.